Display options
Cite
Kitai S, Kudo M, Nishida N, et al. Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver Cancer. 2016;5(3):175-89doi: 10.1159/000367765.
Kitai, S., Kudo, M., Nishida, N., Izumi, N., Sakamoto, M., Matsuyama, Y., Ichida, T., Nakashima, O., Matsui, O., Ku, Y., Kokudo, N., Makuuchi, M. (2016). Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver cancer, 5(3), 175-89. https://doi.org/10.1159/000367765
Kitai, Satoshi, et al. "Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis." Liver cancer vol. 5,3 (2016): 175-89. doi: https://doi.org/10.1159/000367765
Kitai S, Kudo M, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M. Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis. Liver Cancer. 2016 Jul;5(3):175-89. doi: 10.1159/000367765. Epub 2016 May 03. PMID: 27493893; PMCID: PMC4960362.
Copy Download .nbib Format: NLM
Share it on

Liver Cancer. 2016 Jul;5(3):175-89. doi: 10.1159/000367765. Epub 2016 May 03.

Survival Benefit of Locoregional Treatment for Hepatocellular Carcinoma with Advanced Liver Cirrhosis.

Liver cancer

Satoshi Kitai, Masatoshi Kudo, Naoshi Nishida, Namiki Izumi, Michiie Sakamoto, Yutaka Matsuyama, Takafumi Ichida, Osamu Nakashima, Osamu Matsui, Yonson Ku, Norihiro Kokudo, Masatoshi Makuuchi,

Affiliations

  1. Department of Gastroenterology and Hepatology, Kinki University School of Medicine, Osaka-Sayama, Japan.
  2. Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Tokyo, Japan.
  3. Department of Pathology, Keio University School of Medicine, Tokyo, Japan.
  4. Department of Biostatistics, School of Public Health, University of Tokyo, Tokyo, Japan.
  5. Shonan-East General Hospital, Kanagawa, Japan.
  6. Department of Clinical Laboratory Medicine, Kurume University Hospital, Kurume, Japan.
  7. Department of Radiology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan.
  8. hDepartment of Surgery, Kobe University Graduate School of Medicine, Kobe, Japan.
  9. Hepato-Biliary-Pancreatic Surgery Division, Artificial Organ and Transplantation Division, Department of Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
  10. Department of Surgery, Japanese Red Cross Medical Center, Tokyo, Japan.

PMID: 27493893 PMCID: PMC4960362 DOI: 10.1159/000367765

Abstract

BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) with decompensated liver cirrhosis (LC) is a life-threatening condition, which is amenable to liver transplantation (LT) as the standard first-line treatment. However, the application of LT can be limited due to a shortage of donor livers. This study aimed to clarify the effect of non-surgical therapy on the survival of patients with HCC and decompensated LC.

METHODS: Of the 58,886 patients with HCC registered in the nationwide survey of the Liver Cancer Study Group of Japan (January 2000-December 2005), we included 1,344 patients with primary HCC and Child-Pugh (C-P) grade C for analysis in this retrospective study. Among the patients analyzed, 108 underwent LT, 273 were treated by local ablation therapy (LAT), 370 were treated by transarterial chemoembolization (TACE), and 593 received best supportive care (BSC). The effect of LT, LAT, and TACE on overall survival (OS) was analyzed using multivariate and propensity score analyses.

RESULTS: Patient characteristics did not differ significantly between each treatment group and the BSC group, after propensity score matching. LAT (hazard ratio [HR]) =0.568; 95% confidence interval [CI], 0.40-0.80) and TACE (HR=0.691; 95% CI, 0.50-0.96) were identified as significant contributors to OS if the C-P score was less than 11 and tumor conditions met the Milan criteria.

CONCLUSIONS: For patients with HCC within the Milan criteria and with a C-P score of 10 or 11, locoregional treatment can be used as a salvage treatment if LT is not feasible.

Keywords: Best supportive care; Child-Pugh grade C; Local ablation therapy; Transarterial chemoembolization

References

  1. Liver Cancer. 2012 Sep;1(2):71-82 - PubMed
  2. Hepatology. 2004 Dec;40(6):1396-405 - PubMed
  3. Hepatology. 2010 Aug;52(2):762-73 - PubMed
  4. Dig Dis. 2011;29(3):339-64 - PubMed
  5. Liver Cancer. 2013 Apr;2(2):73-83 - PubMed
  6. Liver Cancer. 2013 Aug;2(3-4):338-44 - PubMed
  7. Hepatology. 1987 Jul-Aug;7(4):660-4 - PubMed
  8. Liver Cancer. 2012 Sep;1(2):62-70 - PubMed
  9. Liver Cancer. 2012 Nov;1(3-4):183-9 - PubMed
  10. Br J Cancer. 2008 Apr 8;98(7):1161-5 - PubMed
  11. Liver Cancer. 2013 Aug;2(3-4):332-7 - PubMed
  12. Liver Transpl. 2011 Oct;17 Suppl 2:S44-57 - PubMed
  13. Oncology. 2011;81 Suppl 1:105-10 - PubMed
  14. Gastroenterology. 2006 Aug;131(2):461-9 - PubMed
  15. J Hepatol. 2006 Oct;45(4):529-38 - PubMed
  16. Dig Dis. 2013;31(5-6):490-8 - PubMed
  17. Oncology. 2011;81 Suppl 1:111-5 - PubMed
  18. Surgery. 2013 Apr;153(4):510-7 - PubMed
  19. Liver Cancer. 2012 Jun;1(1):41-50 - PubMed
  20. Hepatology. 2003 Feb;37(2):429-42 - PubMed
  21. N Engl J Med. 1996 Mar 14;334(11):693-9 - PubMed
  22. Eur J Radiol. 2012 Mar;81(3):e277-80 - PubMed
  23. Lancet. 2002 May 18;359(9319):1734-9 - PubMed
  24. CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90 - PubMed
  25. Oncology. 2010 Jul;78 Suppl 1:180-8 - PubMed
  26. Hepatology. 2005 Nov;42(5):1208-36 - PubMed
  27. Oncology. 2010 Jul;78 Suppl 1:78-86 - PubMed
  28. J Hepatol. 2012 Apr;56(4):908-43 - PubMed

Publication Types